Scientists reveal best imaging technique for ovarian cancer

February 15, 2012, Cancer Research UK

Cancer Research UK-funded scientists have determined that a magnetic resonance imaging (MRI) technique, which measures the movement of water molecules within the tumour, may be the best way to monitor how women with late-stage ovarian cancer are responding to treatment. The study is published in the journal Radiology today.

Researchers from Cancer Research UK’s Cambridge Experimental Cancer Medicine Centre at the University of Cambridge compared three different MRI techniques and showed that a type called ‘diffusion-weighted MRI’ is the most effective at indicating response to treatment and also at distinguishing when tumours that had spread from the ovaries into surrounding tissues were not responding.

CT scans are routinely used to help assess whether patients should continue having chemotherapy after their first round of treatment, but can only detect differences in the size of the as opposed to a change in its structure.

Study leader Dr Evis Sala from the University of Cambridge, said: “At the moment we rely on CT scans and blood tests to tell us what’s going on inside a patient’s tumour. But it’s difficult to judge how effective treatment has been from these alone, particularly when the cancer has spread to other tissues where it may behave differently to the primary tumour.

“We’ve shown that diffusion-weighted MRI can give a much better idea of the density of tumours, in addition to their size, making it easier to determine which patients are benefitting most from the treatment. We are now collaborating on a nationwide study to see if this type of imaging could be an effective way of predicting treatment response in a much larger group of patients with advanced ovarian cancer.”

Daphne Tustian, is one of 21 women who took part in the study. She was diagnosed with advanced ovarian cancer in May 2009. Her participation in the study meant that various MRI techniques were used to monitor her throughout her chemotherapy to help inform doctors how her treatment was going. Her cancer went into remission in November 2009, but returned just over a year later.

She said: “I know that at present doctors are trying to prolong my life – they are unable to cure the cancer in my body, but if they can give me more time with my family I am very happy with that.

“When I enrolled on the trial nurses explained to me that it may not benefit me directly but certainly would help others in the future.  I do feel that I have benefitted from the trial, however, as I was closely monitored and knew at each stage how my cancer was responding to treatment. It saved me from having unnecessary chemotherapy and it can save others too. If someone is on chemotherapy and it’s not working it’s a waste of their time, of drugs, of money and a waste of life.”

Each patient underwent an MRI of the abdomen and pelvis, including three additional MRI techniques on top of the standard scans. The different imaging techniques were compared using various parameters - one which was called the Apparent Diffusion Coefficient (ADC), which measures the movement of in tumours.

The researchers compared the ADC measurements in the primary tumour and in cancer cells that had spread from the ovaries into lining of the abdomen. They found there was a larger increase in the ADC of the primary tumour among those who responded to treatment compared to those who didn’t, while in the sites of cancer spread there was no change.

Senior author Dr James Brenton from Cancer Research UK’s Cambridge Research Institute, added: “The increase in ADC seen in the primary tumour in patients who responded to treatment is due to the chemotherapy killing some of the cancer cells, which in turn increases the amount of space inside the tumour allowing water molecules to flow more easily. The fact that there was little change in sites of cancer spread suggests that these cells may be more resistant and so need to be targeted with a different treatment to the primary tumour.”

Dr Joanna Reynolds, Cancer Research UK’s director of centres, said: “A important aim of Cancer Research UK’s Experimental Cancer Medicine Network is to support the development of tests that can help doctors to quickly spot treatment resistant cells in the tumour, so therapy can be tailored appropriately. Advanced ovarian cancer can be very difficult to treat, meaning it’s vital that patients are monitored closely to ensure they are benefiting from treatment. We’re excited to be funding the next stage of this research, which will look at the potential benefits of this test in a much larger group of patients. ”

Explore further: Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

More information: Sala, E., Kataoka, M., Priest, A., Gill, A., McLean, M., Joubert, I., Graves, M., Crawford, R., Jimenez-Linan, M., Earl, H., Hodgkin, C., Griffiths, J., Lomas, D., & Brenton, J. (2012). Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects Radiology DOI: 10.1148/radiol.11110175

Related Stories

Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

December 20, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that the commonest type of ovarian cancer evolves at a startling rate, which may allow cancer cells to ‘dodge’ the current standard treatment, reveals ...

Scientists discover how cancers generate muscle-like contractions to spread around the body

August 16, 2011
Cancer Research UK-funded scientists have discovered that a protein called JAK triggers contractions in tumors which allows cancer cells to squeeze though tiny spaces and spread, in research published in Cancer Cell today.

Gene fault could predict ovarian cancer drug success

June 6, 2011
Faults in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to research at Newcastle University.

New cancer imaging technique uses vitamin C to detect more aggressive tumours

August 4, 2011
Cancer research UK scientists have developed a new imaging technique that uses vitamin C to detect cancers likely to be more aggressive or resistant to treatment, according to a study published in the Journal of the American ...

Reprogrammed oestrogen binding linked to more aggressive breast cancer

January 4, 2012
(Medical Xpress) -- Scientists based at Cancer Research UK’s Cambridge Research Institute have discovered how receptors for the female sex hormone oestrogen attach to a different part of the DNA in breast cancer patients ...

Recommended for you

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.